Patents
Patents for C07C 217 - Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton (13,958)
07/2003
07/02/2003CN1427743A Form of polymer carrier its use in organic chemical synthesis and producing process
07/01/2003US6586559 Polyamide oligomers
07/01/2003US6586475 5-chloro-N-(2-N,N-diethylamino)ethyl)-2- methoxy-4-(1-naphthoylamino)benzamide and prodrugs, used for prevention of neurodegenarative diseases such as Alzheimer's disease
07/01/2003US6586433 Anticholesterol agents; antilipemic agents; cardiovascular disorders
06/2003
06/26/2003WO2003051936A1 Bidentate ligand based catalyst for the polymerization of olefins
06/26/2003US20030119833 Treating cardiovascular diseases
06/26/2003US20030119083 Generating antibodies; binding antigen; therapy for drug overdose
06/26/2003US20030119031 Fluroescence analysis; controlling transcription factors; bactericides, viricides, anticancer agents, fungicides, antiprotozoa agents
06/26/2003CA2468695A1 Bidentate ligand based catalyst for the polymerization of olefins
06/25/2003CN1426391A Polyamine analogues as cytotoxic agents
06/25/2003CN1112349C Process for reducing p(o)-aminomethyl phenoxide by sodium hydroxide and sulfure
06/24/2003US6583183 Substituted n-phenyl-n-fused-benzyl aminoalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity
06/24/2003CA2126337C 2-amino-1,3-propanediol compound and immunosuppressant
06/19/2003WO2003050076A1 Venlafaxine hydrochloride monohydrate and methods for the preparation thereof
06/19/2003WO2003050075A1 Novel crystalline polymorph of venlafaxine hydrochloride and methods for the preparation thereof
06/19/2003WO2003050074A1 Manufacture of venlafaxine hydrochloride and crystalline polymorphs thereof
06/19/2003WO2003050073A1 Substituted hydroxyethylamines
06/19/2003WO2003049666A2 Compounds for a controlled release of active molecules
06/19/2003US20030114711 Hydrogenation of phenylacetonitriles in presence of a nickel or cobalt catalyst
06/19/2003US20030114536 Venlafaxine hydrochloride monohydrate and methods for the preparation thereof
06/19/2003US20030114533 Arylpoly-(oxalkyl) compounds with benzyldimethylamine or substituted benzyl-dimethylamines in a suitable solvent
06/19/2003US20030114454 Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity
06/19/2003US20030111107 Spiro compounds and their use
06/19/2003US20030110578 Such as 2-((2-amino-phenylamino)-methyl)-1,4-diaminobenzene; hair dyes
06/19/2003CA2469622A1 Substituted hydroxyethylamines
06/19/2003CA2468231A1 Compounds for a controlled release of active molecules
06/19/2003CA2467614A1 Venlafaxine hydrochloride monohydrate and methods for the preparation thereof
06/19/2003CA2467593A1 Novel crystalline polymorph of venlafaxine hydrochloride and methods for the preparation thereof
06/18/2003EP1318976A2 Substituted aminopropoxyaryl derivatives useful as agonists for lxr
06/18/2003EP1318803A1 Fatty acid synthase inhibitors
06/18/2003EP1177270B1 Polyalkene alcohol polyetheramines and use thereof in fuels and lubricants
06/18/2003EP1098874B1 Benzocycloheptenes, method for the production thereof, pharmaceutical preparations containing these compounds, and their use for producing medicaments
06/18/2003EP0907631B1 Inorganic ion receptor-active compounds
06/18/2003EP0757677B1 Benzocyclohexylimidazolethione derivatives
06/12/2003WO2003048117A2 Propanolaminomethyltetralines, their preparation and pharmaceutical composition comprising same
06/12/2003WO2003048113A1 Tramadol analogs and uses thereof
06/12/2003WO2003048082A2 Crystalline venlafaxine base and novel polymorphs of venlafaxine hydrochloride, processes for preparing thereof
06/12/2003WO2002017712A3 Disubstituted benzenes as insecticides
06/12/2003US20030109752 Purification of racemic mixtures
06/12/2003US20030109585 Novel crystalline polymorph of venlafaxine hydrochloride and methods for the preparation thereof
06/12/2003US20030109528 Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity
06/12/2003CA2468728A1 Crystalline venlafaxine base and novel polymorphs of venlafaxine hydrochloride, processes for preparing thereof
06/11/2003EP1317461A1 4-cyclohexyl-1,3,2-oxazaborolidine chiral accessories
06/11/2003CN1423630A Quaternary ammonium compounds and their use as anti-tussive agents
06/10/2003US6576795 Racemization of optically active amines
06/10/2003US6576794 Reacting a primary or secondary alcohol with acrylonitrile in presence of an alkali metal hydroxide to obtain alkyloxypropionitrile, adding water without removing alkali metal hydroxide to effect hydrogenation using a catalyst
06/10/2003US6576645 Triphenylalkene derivatives and their use as selective estrogen receptor modulators
06/10/2003US6576260 Sustained-release form of administration containing tramadol saccharinate
06/05/2003WO2003046197A1 Process for preparation of 2-aminotetralin derivatives and intermediates thereof
06/05/2003WO2003045306A2 Phenoxy amine compounds and compositions for delivering active agents
06/05/2003US20030105360 Polymorphic; for inhibiting serotonin uptake in mammals
06/05/2003US20030105359 Having good thermal stability and/or solubility characterisitics
06/05/2003US20030105161 Analgesics; antiinflamamtory agents
06/05/2003US20030105100 Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity
06/04/2003CN1422244A Process for producing amine derivatives
06/04/2003CN1110473C Method for removing contaminants from products
06/03/2003US6573395 Zinc complex with a chiral ligand, such as diethylzinc((S,S)-N-N'-ethylene-bis-(1-phenylethylamine))
06/03/2003US6573278 Aryl sulfonamides and analogues thereof and their use in the treatment of neurodegenerative diseases
06/03/2003US6573252 Therapy and prevention of bony disorders; improved gastrointestinal tolerability
05/2003
05/30/2003WO2002094765A3 Substituted aromatic amide derivative, intermediate thereof, agrohorticultural insecticide containing thereof and method for the use thereof
05/30/2003WO2002092211A3 Bis (perfluoroalkanesulfonyl) imides and their salts as surfactants/additives for applications having extreme environments and methods therefor
05/29/2003US20030100754 Naphthalene compounds, intermediates, formulations, and methods
05/29/2003US20030100616 Administering to a patient for the treatment and/or prophylaxis an effective amount of 3-amino-propoxy derivative as a potent, beta-1-sepcific beta blocker whith a short duration of action in the systemic circulation
05/29/2003US20030100559 Such as 3-((3-(3-trifluoromethoxyphenoxy)phenyl)((3-(1,1,2,2-tetrafluoroethoxy) -phenyl)methyl)amino)-1,1,1-trifluoro-2-propanol for treatment of coronary artery disease
05/28/2003EP1314715A1 Styryl compounds and organic electroluminescent devices
05/28/2003EP1313721A2 Non-imidazole aryloxyalkylamines as h3 receptor ligands
05/28/2003EP1313700A1 10-aryl-11h-benzo[b]fluorene derivatives and analogs as estrogenic compounds
05/28/2003EP1313698A2 Process for the preparation of substituted phenylacetonitriles
05/28/2003EP1313560A1 CATALYST FOR AROMATIC C-O, C-N, and C-C BOND FORMATION
05/28/2003EP1206427A4 Chiral ligands, transition-metal complexes thereof and uses thereof in asymmetric reactions
05/22/2003WO2003042164A1 Aryl aniline beta-2 adrenergic receptor agonists
05/22/2003WO2003042161A1 Venlafaxine hydrochloride polymorphs
05/22/2003WO2003042160A1 Aryl aniline beta-2 adrenergic receptor agonists
05/22/2003WO2003042150A1 Novel bensophenone derivatives or salts thereof
05/22/2003US20030096858 The parent drug compound is modified by forming one or more of predetermined chemical arrangement within parent drug structure for programming specific course and rate of metabolism for drug that leads to inactive nontoxic metabolite
05/22/2003US20030096818 Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity
05/22/2003US20030095992 Altering a drug's distribution, metabolism and elimination properties, especially by modifying with aralkyl ester moieties to increase rate of metabolism to inactive and nontoxic metabolites when exposure is halted; surgery, riots
05/22/2003CA2466962A1 Aryl aniline beta-2 adrenergic receptor agonists
05/21/2003EP1311520A1 Ruthenium complexes containing carboids
05/21/2003EP1311515A2 Amino acid-derived cyclic phosphonamides and methods of synthesizing the same
05/21/2003EP1311499A2 Bicyclic compounds as h3 receptor ligands
05/21/2003EP1311482A2 Non-imidazole aryloxypiperidines as h3 receptor ligands
05/21/2003EP1311471A1 Phenyl- and phenylalkyl-substituted ethanolamines and ethylenediamines
05/21/2003CN1419534A Diphenyl ether compounds useful in therapie
05/20/2003US6565614 Cationic oxidation bases, their use for oxidation dyeing of keratin fibres, dyeing compositions and dyeing methods
05/20/2003CA2197302C Solid support reagents for the synthesis of 3'-nitrogen containing polynucleotides
05/15/2003WO2003040277A2 Branched reaction products
05/15/2003WO2003040096A2 N, n'-substituted-1,3-diamino-2-hydroxypropane derivatives
05/15/2003WO2003040080A2 Lipoxin a4 analogs
05/15/2003WO2003005965A3 Modulators of ceramidase and methods of use based thereon
05/15/2003US20030092870 Low temperature adhesive bonding
05/15/2003US20030092773 Process for the separation of the cis trans diasteroisomers of tramadol
05/15/2003US20030091859 Luminescent material for organic and polymer-based electro-luminescence element and other optical elements
05/15/2003CA2466284A1 N, n'-substituted-1,3-diamino-2-hydroxypropane derivatives
05/14/2003EP1310522A1 Crosslinkable elastomer composition
05/14/2003EP0955806B1 Bioactive compounds
05/13/2003US6563008 Biphenyl compounds and their use as oestrogenic agents
05/13/2003US6562989 Catalyst for aromatic C—O, C—N, and C—C bond formation
05/13/2003US6562817 Suppressants of the IgE production
05/13/2003US6562080 Primary intermediates for oxidative coloration of hair
1 ... 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 ... 140